Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.55 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11568935 | 1.00 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL1858066 | 1.00 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL15156061 | 1.00 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL2090530 | 1.00 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL6062388 | 1.00 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL8430831 | 1.00 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL9932211 | 1.00 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL4603716 | 1.00 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL20746502 | 1.00 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL376410 | 1.00 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125681-A1 | DOUBLE-STRANDED RNAi AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF | HANGZHOU TIANLONG PHARMACEUTICAL CO., LTD. (CN) | 2026-05-07 | — | — | US | claimed |
| EP-4736848-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CATIONIC LIPID AND USE THEREOF | Shanghai Regenelead Therapies Co., Ltd. (CN) | 2026-05-06 | — | — | EP | claimed |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | claimed |
| US-12551500-B2 | C6′-substituted locked nucleic acid-modified cap analog and use thereof | HANGZHOU TIANLONG PHARMACEUTICAL CO., LTD. (CN) | 2026-02-17 | — | — | US | claimed |
| EP-4688003-A2 | LIPOSOMAL COMPOSITIONS OF ARCHEXIN | The Whiteoak Group, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-12545637-B2 | Extrahepatic targeted cationic lipid compound with high efficiency and low toxicity and its composition | BEIJING YOUCARE KECHUANG PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-02-10 | — | — | US | claimed |
| EP-4681728-A2 | HERPES ZOSTER MRNA VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Hangzhou Tianlong Pharmaceutical Co., Ltd. (CN) | 2026-01-21 | — | — | EP | claimed |
| US-20260014244-A1 | RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | HANGZHOU TIANLONG PHARMACEUTICAL CO LTD (CN) | 2026-01-15 | — | — | US | claimed |
| EP-4678747-A2 | DOUBLE-STRANDED RNAI AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF | Hangzhou Tianlong Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| EP-4678741-A1 | RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Hangzhou Tianlong Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| WO-2023070132-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-27 | — | — | WO | claimed |
| WO-2023070133-A2 | COMPOSITIONS AND METHODS OF THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-27 | — | — | WO | claimed |
| WO-2023057574-A2 | INDICATIONS FOR ANTI PRAME BINDERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2023-04-13 | — | — | WO | claimed |
| CN-115927480-A | Gene delivery system based on nucleic acid nanostructure and preparation method and application thereof | 国家纳米科学中心 | 2023-04-07 | — | — | CN | claimed |
| CN-115867654-A | RNA constructs and uses thereof | 生物技术欧洲股份公司 | 2023-03-28 | — | — | CN | claimed |
| CN-115811986-A | Coronavirus vaccine | 生物技术欧洲股份公司 | 2023-03-17 | — | — | CN | claimed |
| CN-115397856-A | RNA compositions targeting claudin-18.2 | 生物技术公司 | 2022-11-25 | — | — | CN | claimed |
| CN-113631177-A | KRAS variant mRNA molecules | 库瑞瓦格股份公司 | 2021-11-09 | — | — | CN | claimed |
| EP-3893909-A2 | KRAS VARIANT MRNA MOLECULES | CureVac AG (DE) | 2021-10-20 | — | — | EP | claimed |
| WO-2020123300-A2 | KRAS VARIANT MRNA MOLECULES | ELI LILLY AND COMPANY (US) | 2020-06-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545637-B2 | Extrahepatic targeted cationic lipid compound with high efficiency and low toxicity and its composition | SLC10A1, SLC10A2, LIPC | CA2 1797/4885CA1 3410/4885GRIK1 3855/4885 |
| US-12551500-B2 | C6′-substituted locked nucleic acid-modified cap analog and use thereof | RNMT, RNGTT, NSUN2 | CA2 1828/4885CA1 3983/4885GRIK1 4501/4885 |
| US-20260014244-A1 | RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | UPF1, SFPQ, SRSF1 | CA2 4317/4885CA1 4803/4885GRIK1 3054/4885 |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | PHAX, RNMT, PRKCZ | CA2 2232/4885CA1 4363/4885GRIK1 1670/4885 |
| US-20260125681-A1 | DOUBLE-STRANDED RNAi AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF | NSUN2, EIF2AK2, METTL16 | CA2 4772/4885CA1 4740/4885GRIK1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.